We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Nearly 14 percent of all drugs in clinical trials eventually win approval from the FDA — a much higher percentage than previously thought, according to a new study from the MIT Sloan School of Management. Read More
The Association for Accessible Medicines’ Biosimilars Council submitted an amicus brief supporting Pfizer in its antitrust lawsuit against Johnson & Johnson, arguing the company’s practices will keep biologics prices high and limit competition from biosimilars. Read More
Eighteen Democratic senators joined Health, Labor, Education and Pensions Committee Ranking Member Patty Murray (Wash.) in calling on the Government Accountability Office to review the Trump administration’s efforts against the opioid addiction crisis. Read More
The FDA proposed a new tactic in its fight against the opioid epidemic — blister packs of smaller quantities of opioid drugs that could give providers better prescription options, especially for drugs like Vicodin and Percocet usually intended for short-term use. Read More
The initiative follows previous joint efforts between the two groups that have saved participating drug plans more than CA$1 billion, or about $810 million U.S., in the last five years. Read More